Key Takeaways
- Bacterial vaginosis (BV) is the most common vaginal condition in women ages 15–44 — more common than yeast infections, and often confused with them.[2]
- BV is caused by an overgrowth of anaerobic bacteria that displaces normal Lactobacillus species; it is not a sexually transmitted infection, but sexual activity is its main risk factor.[1]
- Diagnosis requires at least 3 of 4 Amsel criteria or a Nugent score ≥7 on vaginal Gram stain — you cannot reliably diagnose BV from symptoms alone.[1]
- First-line treatment per the CDC 2021 STI Treatment Guidelines: oral metronidazole 500 mg twice daily for 7 days, or metronidazole gel 0.75% intravaginally for 5 days, or clindamycin cream 2% intravaginally for 7 days.[1]
- Up to 50–66% of women experience recurrence within 12 months. Extended suppressive therapy with metronidazole gel plus intravaginal boric acid is the most evidence-supported approach for recurrent cases.[3]
- BV during pregnancy is associated with roughly a two-fold increased risk of preterm birth and should always be treated.[5]
Bacterial vaginosis is one of the most under-diagnosed conditions I see in telemedicine practice. Patients come in describing discharge and odor, and many have already spent weeks trying over-the-counter yeast infection treatments that made no difference — because BV and yeast infections are entirely different conditions treated with entirely different medications. Treating one with the other does nothing.
BV affects roughly 21 million women in the United States each year.[2] Despite how common it is, it carries real clinical consequences when missed or undertreated: increased susceptibility to HIV and other STIs, elevated risk of pelvic inflammatory disease, and — for pregnant patients — a significantly higher chance of preterm delivery.[1]
This guide reflects the CDC's 2021 STI Treatment Guidelines and the most current clinical evidence. My goal is straightforward: to give you the same information I would give a patient sitting across from me in an exam room.
What Is Bacterial Vaginosis?
Bacterial vaginosis is a condition of vaginal dysbiosis — meaning the normal balance of bacteria in the vagina shifts in a harmful direction. A healthy vagina is dominated by Lactobacillus species, which produce lactic acid and hydrogen peroxide to maintain a pH below 4.5. This acidic environment is the vagina's primary defense against infection.
In BV, Lactobacillus populations drop and anaerobic bacteria move in to fill the space. The main species involved include Gardnerella vaginalis, Prevotella species, Mobiluncus species, Atopobium vaginae, and others.[1] These bacteria raise the vaginal pH above 4.5, produce amines that create the characteristic fishy odor, and form biofilms on the vaginal epithelium that make the condition difficult to cure permanently.
BV is not an infection in the traditional sense — there is no single causative pathogen, no fever, and no tissue invasion. Think of it as an ecosystem collapse. The normal microbial community that protects the vagina breaks down, and opportunistic anaerobes take over the available space.
BV is not classified as a sexually transmitted infection because it is not caused by a single transmissible pathogen. However, it is rare in women who have never been sexually active, and having new or multiple partners is the strongest known risk factor. Semen has an alkaline pH that temporarily disrupts vaginal acidity, which can trigger the bacterial shift that leads to BV. This is why some women notice BV symptoms specifically after intercourse.
Symptoms
One of the clinically frustrating aspects of BV is that up to 84% of women with laboratory-confirmed BV report no symptoms at all.[2] When symptoms are present, they are usually distinct enough to point toward the diagnosis — but not reliable enough to confirm it without testing.
Common Symptoms
- Thin, homogeneous vaginal discharge — often described as milky, gray, or off-white, and coating the vaginal walls evenly
- Fishy vaginal odor — typically stronger after sexual intercourse or during menstruation, when the vaginal pH rises
- Mild vaginal irritation or burning — usually not severe
- Burning with urination — less common than in a UTI, but it can occur
What BV Usually Does Not Cause
- Intense vaginal itching (that's more characteristic of a yeast infection)
- Vulvar redness or swelling
- Fever or pelvic pain (those suggest a different or concurrent infection)
- Thick, clumpy, cottage cheese-like discharge (that's yeast)
When patients describe their symptoms to me, discharge character and odor are the two features I focus on most. A thin, grayish discharge with a noticeable fishy smell after sex is BV until proven otherwise. But I always confirm with testing before prescribing treatment, because clinical impression alone misses a meaningful number of cases.
Causes and Risk Factors
Researchers do not fully understand what triggers the Lactobacillus collapse that starts BV. What we do know is that certain exposures and behaviors consistently increase risk. Understanding these helps explain why some women get BV repeatedly while others never do.
Established Risk Factors
- New or multiple sexual partners: The most consistently identified risk factor across studies. This includes both male and female partners — BV can be transmitted between women who have sex with women.[1]
- Douching: Disrupts the vaginal ecosystem by washing away protective Lactobacillus species and altering pH. No medical organization recommends douching for any reason.
- Lack of condom use: Semen raises vaginal pH and introduces new bacterial species. Consistent condom use reduces BV risk.
- Copper IUD use: Associated with higher BV rates, though the mechanism is not fully established.[1]
- Menses: Menstrual blood raises vaginal pH, creating conditions that favor BV-associated bacteria. BV often flares around menstruation.
- Prior BV episode: Having had BV before is one of the strongest predictors of future recurrence.
- HSV-2 seropositivity: Associated with higher BV prevalence, though the direction of causality is unclear.
Factors That May Be Protective
- Male partner circumcision: Circumcised male partners harbor fewer anaerobic bacteria on the penile skin, which appears to reduce BV transmission risk.[1]
- Hormonal contraception: Some data suggest oral contraceptives or the hormonal IUD may reduce BV incidence, possibly by stabilizing vaginal pH.
- Consistent condom use
Diagnosis
Diagnosing BV requires clinical testing. You cannot confirm it from symptoms alone, and you definitely cannot confirm it from an at-home symptom checker. Many other conditions — including trichomoniasis, cervicitis, and desquamative inflammatory vaginitis — present with similar symptoms. Treating the wrong condition wastes time and risks letting the real problem progress.
Amsel Criteria
The most commonly used clinical diagnostic tool requires at least 3 of the following 4 criteria:[1]
- Homogeneous, thin, whitish discharge that coats the vaginal walls
- Vaginal pH greater than 4.5
- Positive whiff test — a fishy odor released when 10% potassium hydroxide (KOH) is added to vaginal discharge
- Clue cells on wet mount microscopy — vaginal epithelial cells studded with adherent bacteria, giving them a stippled, "moth-eaten" appearance
Clue cells are the single most specific of the four criteria. When I see them on microscopy, the diagnosis is effectively confirmed.
Nugent Score
The Nugent score is the laboratory reference standard. It uses a Gram stain of vaginal discharge to quantify the relative amounts of Lactobacillus morphotypes (normal), Gardnerella and Bacteroides morphotypes (abnormal), and curved rods (Mobiluncus). Scores range from 0–10; a score of 7–10 indicates BV, 4–6 is intermediate, and 0–3 is normal. Sensitivity and specificity are higher than Amsel criteria in research settings, but Amsel criteria remain more practical in clinical practice.
Newer Point-of-Care and Molecular Tests
FDA-cleared nucleic acid amplification tests (NAATs) — including the BD Max Vaginal Panel and the Aptima BV assay — offer high sensitivity and specificity and are increasingly available in clinic and telehealth settings. These tests detect the DNA of BV-associated organisms directly and do not require microscopy. For patients who need rapid, accurate diagnosis, molecular testing is a reliable option.[3]
Treatment
The 2021 CDC STI Treatment Guidelines recommend antibiotic treatment for all women with symptomatic BV.[1] Treatment has two goals: relieve symptoms and reduce the downstream risks associated with BV — including STI susceptibility and, in pregnant patients, obstetric complications.
First-Line Regimens
| Antibiotic | Regimen | Key Notes |
|---|---|---|
| Metronidazole (oral) | 500 mg twice daily for 7 days | Most common first-line option. Effective and well-tolerated. The previous warning about alcohol is no longer supported by evidence — current data shows no reliable disulfiram-like interaction at this dose.[1] Avoid during the first trimester of pregnancy if possible. |
| Metronidazole gel 0.75% (intravaginal) | One full applicator (5 g) intravaginally once daily for 5 days | Good option for patients who want to avoid oral medication. Lower systemic absorption than oral metronidazole. Applied at bedtime is easiest for most patients. |
| Clindamycin cream 2% (intravaginal) | One full applicator (5 g) intravaginally at bedtime for 7 days | Oil-based formulation — can weaken latex condoms and diaphragms for up to 5 days after use. Preferred option in patients with metronidazole allergy or intolerance. |
Alternative Regimens
When first-line options are contraindicated or not tolerated, the CDC recognizes several alternatives:[1]
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days (oil-based; same condom caution applies for 72 hours)
- Secnidazole 2 g oral granules as a single dose (sprinkled on soft food like yogurt or applesauce) — convenient single-dose option with phase 3 trial support[3]
- Tinidazole 2 g orally once daily for 2 days, or 1 g once daily for 5 days
What I Tell Patients About Treatment
Finish the full course, even if symptoms improve after 2–3 days. Stopping early is one of the reasons BV recurs — the bacterial population is suppressed but not fully cleared. Also, refrain from sexual activity or use condoms consistently during treatment; introducing semen or a new partner's microbiome during treatment undermines the antibiotic's effect.
Douching during or after treatment is specifically contraindicated. I see patients who rinse intravaginally after applying gel because it "feels cleaner." That approach washes away the medication and restores exactly the conditions that caused the BV in the first place.
Recurrent BV: Management Approach
Recurrent BV is one of the most frustrating clinical problems in women's health. Standard antibiotic treatment achieves cure rates of 80–90% initially — but up to 50–66% of women experience recurrence within 12 months.[3] For some patients, BV returns within weeks of completing treatment. This is not a treatment failure in the conventional sense; it reflects the biology of the condition.
Two mechanisms drive recurrence. First, antibiotics suppress BV-associated bacteria but do not restore Lactobacillus populations. Once antibiotics clear, the ecological conditions that allowed BV to develop in the first place may still be present. Second, Gardnerella vaginalis forms dense biofilms on the vaginal epithelium that antibiotics penetrate poorly — these biofilm communities can repopulate the vagina even after apparently successful treatment.[3]
Suppressive Therapy Options
For women with three or more episodes in a 12-month period, the CDC outlines several suppressive strategies:[1]
- Extended metronidazole gel: Metronidazole gel 0.75% once daily for 10 days, then twice weekly for 16 weeks. This regimen demonstrates approximately 70% protection against recurrence compared to placebo, though recurrence rates climb again after stopping.[3]
- Oral nitroimidazole + boric acid: Metronidazole or tinidazole 500 mg orally twice daily for 7 days, followed by intravaginal boric acid 600 mg daily for 21 days, then metronidazole gel twice weekly for 4–6 months. This combination targets both the active infection and the biofilm component. Recurrence rates at 6 months are roughly 30% — better than standard single-course therapy.[1]
- Monthly metronidazole plus fluconazole: Metronidazole 2 g orally combined with fluconazole 150 mg once monthly has been evaluated as a suppressive regimen and may reduce BV incidence while addressing concurrent yeast overgrowth (a common side effect of repeated metronidazole courses).[1]
The 2025 Male Partner Treatment Data
A 2025 randomized controlled trial published in the New England Journal of Medicine found that treating male sexual partners — oral metronidazole 400 mg twice daily plus 2% clindamycin cream applied to the penile skin, both for 7 days — reduced BV recurrence in female partners from 63% to 35% at 12 weeks.[4] This is a meaningful finding. The CDC's 2021 guidelines did not recommend routine male partner treatment, but this trial may change that guidance in the next update. For my patients with highly recurrent BV in monogamous relationships, this is a conversation worth having with your provider now.
What About Probiotics?
I get asked about probiotics for BV frequently. The short answer: oral and vaginal probiotic formulations have shown mixed results in clinical trials, and the CDC does not currently recommend them as either adjunctive or replacement therapy.[1] Vaginal Lactobacillus crispatus (Lactin-V) showed promise in a phase 2b trial, reducing recurrence rates at 12 weeks when used after standard metronidazole treatment — but it is not yet FDA-cleared or commercially available in the U.S. as of early 2026.[1]
BV vs. Yeast Infection: How to Tell the Difference
This is the question I get most often in telemedicine visits. The two conditions share some surface-level similarities — both affect the vagina, both cause abnormal discharge, and both involve disruption of the vaginal ecosystem. But they are caused by completely different organisms, require different treatments, and have different clinical signatures.
| Feature | Bacterial Vaginosis | Yeast Infection (Candidiasis) |
|---|---|---|
| Cause | Bacterial dysbiosis — overgrowth of anaerobic bacteria | Fungal overgrowth, most often Candida albicans |
| Discharge | Thin, homogeneous, gray or white, milky | Thick, clumpy, white ("cottage cheese") |
| Odor | Fishy, especially after sex or during menses | Little to no odor |
| Itching | Mild or absent | Intense itching and irritation — usually the dominant symptom |
| Vulvar appearance | Usually normal — no redness or swelling | Redness, swelling, and sometimes small fissures |
| Vaginal pH | Elevated: above 4.5 | Normal: below 4.5 |
| Treatment | Antibiotics (metronidazole, clindamycin) | Antifungals (fluconazole, miconazole, clotrimazole) |
| OTC treatment? | No — prescription only | Yes — many effective OTC antifungals available |
The practical take: if the dominant symptom is a strong fishy odor with thin discharge and minimal itching, think BV. If intense itching and thick white discharge are the main problems, think yeast. If you have both odor and significant itching, you may have both conditions simultaneously — which is not unusual, especially after a course of antibiotics for BV (antibiotics can trigger secondary yeast overgrowth).
What matters clinically is that treating a yeast infection when you have BV — and vice versa — does nothing. A significant number of women who self-diagnose and self-treat with OTC antifungals actually have BV, which explains why the symptoms don't resolve. Get a proper diagnosis before treating.
When to See a Doctor
Use this framework to decide your next step:
| Scenario | What to Do |
|---|---|
| Thin, grayish discharge with fishy odor after sex; no fever, no pelvic pain | See a doctor within 1–2 days. Classic BV presentation — requires prescription antibiotics. |
| Symptoms you've treated with OTC yeast products that aren't improving | See a doctor now. You likely have BV or trichomoniasis, not a yeast infection. OTC antifungals will not help. |
| Third or more BV episode in the past year | See a doctor for a recurrent BV management plan — standard short courses are not adequate at this point. |
| BV symptoms during pregnancy — any trimester | See a doctor promptly. BV in pregnancy requires treatment to reduce preterm birth and other obstetric risks. |
| Vaginal discharge with pelvic or lower abdominal pain, fever, or pain during sex | See a doctor same day — urgent evaluation needed. These symptoms suggest pelvic inflammatory disease (PID), which requires prompt treatment. |
| High fever, severe pelvic pain, vomiting, or inability to keep fluids down | Go to the emergency department. May indicate severe PID, tubo-ovarian abscess, or another serious complication requiring IV antibiotics. |
- Pelvic or lower abdominal pain — especially if new and constant, not just cramping
- Fever above 101°F (38.3°C) — BV itself does not cause fever; fever with vaginal symptoms suggests a systemic infection
- Painful intercourse combined with discharge or odor
- Any BV symptoms during pregnancy — treat promptly, do not wait
- No improvement after completing a full course of antibiotics — needs a culture-guided approach
- Symptoms along with new or multiple sexual partners — concurrent STI testing is indicated
Prevention
No prevention strategy completely eliminates BV risk, but several practical steps reduce the frequency of recurrence in women who are prone to it. I review these with every patient who has had more than one episode.
What the Evidence Supports
- Use condoms consistently: Barrier protection reduces semen exposure and partner-introduced bacteria. This is the single most modifiable behavioral risk factor supported by evidence.
- Stop douching entirely: No medical benefit exists, and the harms to vaginal flora are well-documented. This applies to all vaginal washes, fragrant soaps, and "feminine hygiene" rinses used internally.
- Avoid new or multiple sexual partners when possible: Not always practical advice, but it's worth naming that partner transitions are a consistent BV trigger.
- Wipe front to back after bowel movements to avoid introducing gut bacteria into the vaginal area.
- Wear breathable underwear and avoid prolonged moisture in the genital area (tight synthetic fabrics, wet swimwear).
What Is Still Under Investigation
Vaginal probiotic preparations containing Lactobacillus crispatus are the most promising avenue for prevention, based on phase 2 trial data.[1] Several clinical trials are ongoing. Boric acid vaginal suppositories are sometimes used as a supportive adjunct for recurrent BV, but they should not be used during pregnancy and are not a standalone replacement for antibiotic treatment. Biofilm-disrupting agents (like TOL-463) are in early trial phases and may eventually become part of the standard recurrent BV toolkit.
Frequently Asked Questions
BV can occasionally resolve on its own, but this is not predictable or reliable enough to count on. Without antibiotics, symptoms often persist or worsen, and untreated BV increases your risk of STI acquisition, pelvic inflammatory disease, and — in pregnancy — preterm birth. The CDC recommends antibiotic treatment for all women with symptoms.[1] Don't try to wait it out beyond a day or two, and never wait if you are pregnant.
BV is not classified as a sexually transmitted infection. It develops from a disruption in the vaginal bacterial ecosystem, not transmission of a single pathogen from a partner. That said, it is rare in women who have never been sexually active, and having new or multiple partners is the strongest known risk factor.[1] Male partners are not treated routinely (though 2025 trial data may change this for recurrent cases). BV can be passed between female sexual partners and should prompt both partners to be evaluated.
The key symptom differences: BV causes thin, gray or white discharge with a strong fishy odor, especially noticeable after sex. Yeast infections cause thick, white, cottage cheese-like discharge with intense itching but little to no odor. BV rarely causes significant itching. Vaginal pH is elevated in BV (above 4.5) but normal in a yeast infection. The only reliable way to know is a clinical exam — many women who self-diagnose a yeast infection actually have BV, which explains why OTC antifungal treatment doesn't help.
Recurrent BV is common — up to 50–66% of women experience a recurrence within 12 months of treatment.[3] Two main reasons: antibiotics treat symptoms but don't restore protective Lactobacillus bacteria, and Gardnerella vaginalis forms biofilms on the vaginal walls that resist antibiotic penetration and allow bacteria to repopulate after treatment ends. Sexual activity with the same partner can also reintroduce the bacterial imbalance. Management for recurrent BV should include extended suppressive metronidazole therapy, intravaginal boric acid, and a conversation about partner treatment based on recent trial data.
Yes — BV during pregnancy requires prompt treatment. BV is associated with roughly a two-fold increased risk of preterm birth, premature rupture of membranes, intra-amniotic infection, and postpartum endometritis.[5] Persistent BV (requiring three or more treatment courses) is associated with an even higher preterm birth risk.[6] The CDC recommends treating all symptomatic pregnant women with oral metronidazole 500 mg twice daily for 7 days, or oral clindamycin 300 mg twice daily for 7 days — both are considered safe during pregnancy.[1] Routine screening of asymptomatic pregnant women for BV is not currently recommended, as treatment has not been shown to prevent preterm birth in low-risk pregnancies.
No FDA-approved over-the-counter treatment for BV exists. Metronidazole and clindamycin — the antibiotics used to treat BV — are available by prescription only. Some women use boric acid vaginal suppositories as a supportive measure for recurrent BV, but boric acid is not first-line therapy, is not FDA-approved for BV specifically, and must never be used during pregnancy. If you suspect BV, see a clinician for a confirmed diagnosis and proper treatment. Self-treating with yeast infection products will not resolve BV and will delay effective care.
References
- Centers for Disease Control and Prevention (CDC). Bacterial Vaginosis — STI Treatment Guidelines, 2021. Last updated July 22, 2021. https://www.cdc.gov/std/treatment-guidelines/bv.htm
- Centers for Disease Control and Prevention (CDC). About Bacterial Vaginosis (BV). Last reviewed December 2023. https://www.cdc.gov/bacterial-vaginosis/about/index.html
- Sobel JD, Sobel R. Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence-Based Guidelines. Clinical Infectious Diseases. 2022;74(Suppl 2):S144–S151. https://academic.oup.com/cid/article/74/Supplement_2/S144/6567952
- Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. New England Journal of Medicine. 2025;392:903–912. https://pubmed.ncbi.nlm.nih.gov/40043236/
- Hoang DM, Kuppusamy G, Omar MH, et al. Maternal and fetal outcomes of pregnant women with bacterial vaginosis. Frontiers in Surgery. 2023;10:984714. https://pmc.ncbi.nlm.nih.gov/articles/PMC9968788/
- March of Dimes Prematurity Research Center, Stanford. Persistent Vaginal Infection Linked to Higher Preterm Birth Risk. July 2024. https://www.marchofdimes.org/our-work/research/blog/persistent-vaginal-infection-tied-to-increased-preterm-birth-risk-stanford-doctors-find
- Muzny CA, Blanchard E, Bhatt D, et al. Effect of bacterial vaginosis on preterm birth: a meta-analysis. BJOG. 2023;130(2):132–139. https://pubmed.ncbi.nlm.nih.gov/36251068/